RyCarma’s lead program, surlorian (also known as ARM210 and S48168), is in development for the treatment of heart failure and ryanodine receptor 1-related myopathies (RYR1-RM). For more ...

and ryanodine receptor 1-related myopathies (RYR1-RM). “Dr. Tarka’s expertise in clinical strategy including the design, implementation, and medical oversight of late-stage clinical trials ...

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up for any (or all) of our 25+ Newsletters. Some states have laws and ethical rules regarding solicitation ...

The clinical approach, epidemiology, diagnostic procedures, and management, along with followup of superficial spreading malignant melanoma are discussed. A 45-year-old Caucasian female presented ...

In this role, Dr. Tarka will lead the clinical development of surlorian (ARM210) as it advances into Phase 2 trials for heart failure with reduced ejection fraction (HFrEF) and ryanodine receptor ...

Muscle contraction is initiated by releasing calcium from the sarcoplasmic reticulum through the ryanodine receptor channels gated mechanically by four dihydropyridine receptors of T-tubules. The ...

1 Guangdong Provincial People’s Hospital, Zhuhai Hospital (Jinwan Central Hospital of Zhuhai), Zhuhai, Guangdong, China 2 Affiliated Hospital of Qingdao University, Qingdao Cancer Institute, Qingdao ...